Inhibitor screening for patients with hemophilia in Turkey

Turkish Journal of Hematology

Volumn 23, Issue 1, 2006, Pages 25-32

  Kavakli, Kaan ^a   Aktuǧlu, Gülten ^b   Kemahli, Sabri ^c   Başlar, Zafer ^b   Ertem, Mehmet ^c   Balkan, Can ^a   Ar, Cem ^b   Yilmaz Karapinar, Deniz ^c   Bilenoǧlu, Basri ^c   Gülseven, Muhterem ^b   Gürman, Ceyda ^c  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Bethesda test; Hemophilia; Inhibitor; Inhibitor prevalence

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; ARTICLE; BLEEDING DISORDER; BLOOD SAMPLING; CHILD; DISEASE SEVERITY; ELECTIVE SURGERY; FREQUENCY ANALYSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; TURKEY (REPUBLIC); VON WILLEBRAND DISEASE;

EID: 33745021430     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aledort L. Inhibitors in hemophilia patients: current status and managements. Am J Hematol 1994;47: 208-17.
2. Brettler DG. Inhibitors of factor VIII and IX. Hemophilia 1995;1(Suppl 1):35-9.
3. Kavakli K. Treatment of inhibitor patients in developing countries. In: Sohail MT, Heijnen L, eds. Comprehensive Hemophilia Care in Developing Countries. Lahore, Pakistan: Ferozsons Ltd., 2001:121-31.
4. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and EK inhibitors in hemophiliacs. Lancet 1992;339:594-8.
5. Kreuz W, Escuriola-Ettinghausen C, Martinez-Saguer I, Gungor T, Kornhuber B. Epidemiology of inhibitors in hemophilia A. Vox Sang 1996;70(Suppl 1):2-8.
6. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in hemophilia A: introduction and systematic review of current practise. Hemophilia 2003;9:405-17.
7. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Hemophilia 2003;9:418-35.
8. Aktuglu G, Kemahli K, Devecioglu O, Kavakli K. Hemophilia registration system in Turkey. 3rd National Congress of Hemophilia, Istanbul, 2001:69-74.
9. Kasper CK, Aledort LA, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorh 1975;34:869-72.
10. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Improved specificity and reliability. Thromb Hemost 1995;73:247-51.
11. Kavakli K, Nişli G, Aydinok Y, Oztop S, Çetingül N, Aydoǧdu S, Yalman O. Prophylactic therapy for hemophilia in a developing country, Turkey. Pediatr Hematol Oncol 1997;14:151-9.
12. Kavakli K, Gringeri A, Bader R, Nişli G, Polat A, Aydinok Y. Inhibitor development and substutition therapy in a developing country: Turkey. Hemophilia 1998;4:104-8.
13. Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in hemophiliacs: a single-center experience over 34 years, 1964-97. Br J Hematol 1999;104: 909-14.
14. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Hemost 1992;67: 600-2.
15. Rizza CR, Spooner R-JD, Giangrande PLF. Treatment of hemophilia in United Kingdom 1981-1996. Hemophilia 2001;7:349-59.
16. Ghosh K, Shetty S, Kulkarni B, Nair S, Pawar A, Khare A. Development of inhibitors in patients with hemophilia from India. Haemophilia 2001;7:273-8.
17. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate PUP Study Group. N Engl J Med 1993;328:453-8.
18. Bray GL, Gomperts ED, Courier SG. A multicenter study of recombinant FVIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1997;83:2428-35.
19. Gursel T, Ezer U, Ozturk G, et al. Hemofilik cocuklarda inhibitor sikligi: bir kohort çalişma(Turkish). XXIV. National Congress of Hemophilia, Istanbul, 1996, 101.
20. Oren H, Yaprak I, Irken G. Factor VIII inhibitors in patients with haemophilia A. Acta Hematol 1999;102:42-6.
21. Kavakli K, Nişli G, Polat A, Aydinok Y. Hepatitis C virus and the treatment of hemophilia in Turkey. Transfusion 1998;38:798-9.
22. Onay UV, Kavakli K, Kilinç Y, Gurgey A, Aktuǧlu G, Kemahli S, Ozbek U, çaǧlayan SH. Molecular pathology of hemophilia B in Turkish patients: identicication of a large deletion and 33 independent point mutations. Brit J Haematol 2003;120:656-9.
23. Aledort LA, DiMichele DM. Inhibitors occur more frequently in African-American and Latino hemophiliacs. Hemophilia 1998;4:68.
24. Lindgren A, Wadenwik H, Tengborn L. Characterization of inhibitors to FVIII with an ELISA in congenital and acquired hemophilia A. Hemophilia 2002;8:644-8.